Professor | Xiu Feng Pang | Asia Growth Partners

Name	Xiu Feng Pang
Contact Information	xfpang@bio.ecnu.edu.cn
Language ability	English, Chinese
Province	Shanghai

Name

Xiu Feng Pang

Contact Information

xfpang@bio.ecnu.edu.cn

Language ability

English, Chinese

Province

Shanghai

University/Lab Affiliation and Title	East China Normal University
Faculty	Life Sciences
Academic Background & Achievements	2007-10 to 2009-10 - PhD in Tumor and Stem Cell Biology, Texas A&M University Health Science Center, USA (Joint Training) 2004-09 to 2009-06 - PhD in Biomedical Science, East China Normal University 2000-09 to 2004-06 - Bachelor in Biotechnology, East China Normal University
Work Experience	2022-01 to present - Professor, School of Life Sciences, East China Normal University 2018-12 to 2021-12 - Researcher, School of Life Sciences, East China Normal University 2015-09 to 2016-09 - Visiting Scholar, National Cancer Institute, NIH, USA 2012-07 to 2018-12 - Associate Researcher, School of Life Sciences, East China Normal University 2009-07 to 2012-07 - Lecturer, School of Life Sciences, East China Normal University
Awards	2021: Recipient of the National Natural Science Foundation of China Excellent Young Scientists Fund 2020: Selected for the Shanghai Municipal Universities Special Professor Plan 2018: Selected for the Shanghai Pujiang Talent Plan 2016: Selected as one of China's Top Ten Emerging Sci-Tech Personalities 2010: Selected for the Shanghai Municipal Education Commission's Morning Light Scholar Plan

University/Lab Affiliation and Title

East China Normal University

Faculty

Life Sciences

Academic Background & Achievements

2007-10 to 2009-10 - PhD in Tumor and Stem Cell Biology, Texas A&M University Health Science Center, USA (Joint Training)
2004-09 to 2009-06 - PhD in Biomedical Science, East China Normal University
2000-09 to 2004-06 - Bachelor in Biotechnology, East China Normal University

Work Experience

2022-01 to present - Professor, School of Life Sciences, East China Normal University
2018-12 to 2021-12 - Researcher, School of Life Sciences, East China Normal University
2015-09 to 2016-09 - Visiting Scholar, National Cancer Institute, NIH, USA
2012-07 to 2018-12 - Associate Researcher, School of Life Sciences, East China Normal University
2009-07 to 2012-07 - Lecturer, School of Life Sciences, East China Normal University

Awards

2021: Recipient of the National Natural Science Foundation of China Excellent Young Scientists Fund
2020: Selected for the Shanghai Municipal Universities Special Professor Plan
2018: Selected for the Shanghai Pujiang Talent Plan
2016: Selected as one of China's Top Ten Emerging Sci-Tech Personalities
2010: Selected for the Shanghai Municipal Education Commission's Morning Light Scholar Plan

Areas of Focus	Tumor biology and molecular targeted therapy Tumor resistance mechanisms and drug combination strategies
Publications	Design, synthesis and pharmacological evaluation of multisubstituted pyrido[4,3-d]pyrimidine analogues bearing deuterated methylene linkers as potent KRASG12D inhibitors, Xiao X, Feng J, Ma J, Xia X, Liu X, Zhang J, Ding C, Pang X, Zhang A, 2023 Loss of PHF8 induces a viral mimicry response by activating endogenous retrotransposons, Liu Y, Hu L, Wu Z, Yuan K, Hong G, Lian Z, Feng J, Li N, Li D, Wong J, Chen J, Liu M, He J, Pang X, 2023 Discovery of a potent and oral complex I OXPHOS inhibitor that abrogates tumor growth and circumvents MEKi resistance, He P, Feng J, Xia X, Sun Y, He J, Guan T, Peng Y, Zhang X, Liu M, Pang X, Chen Y, 2023 Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer, Feng J, Hu Z, Xia X, Liu X, Lian Z, Wang H, Wang L, Wang C, Zhang X, Pang X, 2023 Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in KRAS-mutant lung cancer, Feng J, Lian Z, Xia X, Lu Y, Hu K, Zhang Y, Liu Y, Hu L, Yuan K, Sun Z, Pang X, 2023 BCL6 is regulated by the MAPK/ELK1 axis and promotes KRAS-driven lung cancer, Li K, Liu Y, Ding Y, Zhang Z, Feng J, Hu J, Chen J, Lian Z, Chen Y, Hu K, Chen Z, Cai Z, Liu M, Pang X, 2022 The oncoprotein BCL6 enables solid tumor cells to evade genotoxic stress, Liu Y, Feng J, Yuan K, Wu Z, Hu L, Lu Y, Li K, Guo J, Chen J, Ma C, Pang X, 2022 Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitor, Jiang B, Hu J, Liu H, Liu Z, Wen Y, Liu M, Zhang H, Pang X, Yu L, 2022 BCL6 confers KRAS-mutant non-small-cell lung cancer resistance to BET inhibitors, Guo J, Liu Y, Lv J, Zou B, Chen Z, Li K, Feng J, Cai Z, Wei L, Liu M, Pang X, 2021 Blocking STAT3 by Pyrvinium Pamoate Causes Metabolic Lethality in KRAS-mutant Lung Cancer, Feng J, Jiang W, Liu Y, Huang W, Hu K, Li K, Chen J, Ma C, Sun Z, Pang X, 2020 Suppression of the SLC7A11/glutathione Axis Causes Synthetic Lethality in KRAS-mutant Lung Adenocarcinoma, Hu K, Li K, Lv J, Feng J, Chen J, Wu H, Cheng F, Jiang W, Wang J, Pei H, Chiao PJ, Cai Z, Chen Y, Liu M, Pang X, 2020 Repurposing Sertraline Sensitizes Non-Small Cell Lung Cancer Cells to Erlotinib by Inducing Autophagy, Jiang X, Lu W, Shen X, Wang Q, Lv J, Liu M, Cheng F, Zhao Z, Pang X, 2018 Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo, Yu W, Lu W, Chen G, Cheng F, Su H, Chen Y, Liu M, Pang X, 2017 Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK, Wang J, Hu K, Guo J, Cheng F, Lv J, Jiang W, Lu W, Liu J, Pang X, Liu M, 2016

Areas of Focus

Tumor biology and molecular targeted therapy
Tumor resistance mechanisms and drug combination strategies

Publications

Design, synthesis and pharmacological evaluation of multisubstituted pyrido[4,3-d]pyrimidine analogues bearing deuterated methylene linkers as potent KRASG12D inhibitors, Xiao X, Feng J, Ma J, Xia X, Liu X, Zhang J, Ding C, Pang X*, Zhang A*, 2023
Loss of PHF8 induces a viral mimicry response by activating endogenous retrotransposons, Liu Y, Hu L, Wu Z, Yuan K, Hong G, Lian Z, Feng J, Li N, Li D, Wong J, Chen J, Liu M, He J*, Pang X*, 2023
Discovery of a potent and oral complex I OXPHOS inhibitor that abrogates tumor growth and circumvents MEKi resistance, He P, Feng J, Xia X, Sun Y, He J, Guan T, Peng Y, Zhang X, Liu M, Pang X*, Chen Y*, 2023
Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer, Feng J, Hu Z, Xia X, Liu X, Lian Z, Wang H, Wang L, Wang C, Zhang X*, Pang X*, 2023
Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in KRAS-mutant lung cancer, Feng J, Lian Z, Xia X, Lu Y, Hu K, Zhang Y, Liu Y, Hu L, Yuan K, Sun Z*, Pang X*, 2023
BCL6 is regulated by the MAPK/ELK1 axis and promotes KRAS-driven lung cancer, Li K, Liu Y, Ding Y, Zhang Z, Feng J, Hu J, Chen J, Lian Z, Chen Y, Hu K, Chen Z, Cai Z, Liu M, Pang X*, 2022
The oncoprotein BCL6 enables solid tumor cells to evade genotoxic stress, Liu Y, Feng J, Yuan K, Wu Z, Hu L, Lu Y, Li K, Guo J, Chen J, Ma C*, Pang X*, 2022
Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitor, Jiang B, Hu J, Liu H, Liu Z, Wen Y, Liu M, Zhang H, Pang X*, Yu L*, 2022
BCL6 confers KRAS-mutant non-small-cell lung cancer resistance to BET inhibitors, Guo J, Liu Y, Lv J, Zou B, Chen Z, Li K, Feng J, Cai Z, Wei L, Liu M, Pang X*, 2021
Blocking STAT3 by Pyrvinium Pamoate Causes Metabolic Lethality in KRAS-mutant Lung Cancer, Feng J, Jiang W, Liu Y, Huang W, Hu K, Li K, Chen J, Ma C*, Sun Z*, Pang X*, 2020
Suppression of the SLC7A11/glutathione Axis Causes Synthetic Lethality in KRAS-mutant Lung Adenocarcinoma, Hu K, Li K, Lv J, Feng J, Chen J, Wu H, Cheng F, Jiang W, Wang J, Pei H, Chiao PJ, Cai Z, Chen Y*, Liu M*, Pang X*, 2020
Repurposing Sertraline Sensitizes Non-Small Cell Lung Cancer Cells to Erlotinib by Inducing Autophagy, Jiang X, Lu W, Shen X, Wang Q, Lv J, Liu M, Cheng F*, Zhao Z*, Pang X*, 2018
Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo, Yu W, Lu W, Chen G, Cheng F, Su H, Chen Y, Liu M, Pang X*, 2017
Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK, Wang J, Hu K, Guo J, Cheng F, Lv J, Jiang W, Lu W, Liu J, Pang X*, Liu M*, 2016

Tumor Biology Molecular Therapy Targeted Resistance Mechanisms Drug Combination Strategies

Yue Lou - Shanghai Normal University

Quanhua Wang - Shanghai Normal University

Weihua Huang - Shanghai Normal University

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us